Citation Tools
PDFRegular and young investigator award abstracts
Immune-stimulants and immune modulators
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models